Plasma Fractionation Market Size, Global Trends and Regional Insights to 2032

WESTFORD, Mass. - Feb. 26, 2025 - PRLog -- The plasma fractionation market is poised for significant growth over the coming years, driven by the increasing demand for plasma-derived therapies, advancements in medical technologies, and the rising prevalence of chronic diseases and rare conditions requiring immunoglobulin therapies. Plasma fractionation refers to the process of separating blood plasma into its various components, which are then used in the production of life-saving medications, including immunoglobulins, clotting factors, and albumin. These therapies play a vital role in treating disorders such as hemophilia, autoimmune diseases, and immune deficiencies.

Plasma fractionation is a highly specialized process, and its demand is closely tied to the increasing number of patients requiring plasma-derived therapies. This has been further propelled by growing awareness regarding rare diseases, the rising elderly population, and expanding healthcare infrastructure. The market is also benefiting from technological innovations in plasma separation techniques, making the process more efficient, scalable, and cost-effective.

Get a Free Sample Copy - https://www.skyquestt.com/sample-request/plasma-fractiona...

Market Size & Forecast

The global plasma fractionation market was valued at USD 36.2 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 8.3% from 2025 to 2032. By 2032, the market is projected to reach USD 68.52 billion. This growth trajectory is driven by increasing therapeutic demand, the development of advanced fractionation technologies, and an expanding focus on improving healthcare outcomes in emerging regions.

Top Player's Company Profiles in Plasma Fractionation Industry

CSL Behring (Australia)
Grifols (Spain)
Octapharma (Switzerland)
Kedrion (Italy)
China Biologic Products Holdings (China)
Sanquin (Netherlands)
Bio Products Laboratory (UK)
Japan Blood Products Organization (Japan)
LFB Group (France)
Shanghai RAAS Blood Products (China)
Green Cross Corporation (South Korea)
Baxter International Inc. (US)
Takeda Pharmaceutical Company Limited (Japan)
Beijing Tiantan Biological Products (China)
Biotest AG (Germany)
China National Pharmaceutical Group Co. (Sinopharm) (China)
GC Pharma (South Korea)
ADMA Biologics (US)
Emergent BioSolutions (US)
Renishaw plc (UK)
HP Inc. (USA)

Read Plasma Fractionation Market Report Today - https://www.skyquestt.com/report/plasma-fractionation-market

The plasma fractionation market is expected to grow substantially between 2025 and 2032, driven by increasing therapeutic demand, advancements in plasma separation technologies, and an expanding global healthcare infrastructure. While challenges such as high costs and ethical concerns remain, ongoing research, technological advancements, and a rising focus on healthcare in emerging markets are set to propel the market toward long-term growth. As the healthcare industry continues to prioritize plasma-derived therapies, the global plasma fractionation market is well-positioned for continued expansion.